Traver Hart, Ph.D.
Department of Systems Biology, Division of Discovery Science
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Professor (Joint appointment), Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2008 | The University of Texas at Austin, Austin, Texas, US, Ph.D. in Cell & Molecular Biology |
| 2003 | University of Texas at Austin, Austin, Texas, US, BA in Middle Eastern Studies |
Postgraduate Training
| 2012-2015 | Postdoctoral Fellow, Cancer Functional Genomics, University of Toronto, Toronto |
| 2009-2012 | Postdoctoral Fellow, Genomics/Immunology, The Scripps Research institute, La Jolla, California |
Experience & Service
Administrative Appointments/Responsibilities
Program Director, GSBS, Houston, Texas, 2022 - Present
Co-Director, GSBS, Houston, Texas, 2018 - 2022
Other Professional Positions
Postdoctoral Fellow, Donnelly Centre for Cellular & Biomolecular Research, University of Toronto, Toronto, 2012 - 2015
Postdoctoral Fellow, Scripps Translational Science Institute/TSRI, La Jolla, CA, 2009 - 2012
Graduate Research Assistant/Postdoctoral Fellow, University of Texas at Austin, Austin, TX, 2003 - 2009
Senior Product Manager, Broadwing Inc, Austin, TX, 2000 - 2002
Senior Consultant, Empower Solutions LLC, San Juan, PR, 1999 - 2000
Systems Operations Manager, Ambac Connect Inc, Austin, TX, 1997 - 1999
President and Co-founder, Commercial Internet Services, Herndon, VA, 1995 - 1997
Intelligence Officer, Central Intelligence Agency, Washington, DC, 1990 - 1995
Intramural Institutional Committee Activities
Faculty Representative, Research Data Management, The University of Texas MD Anderson Cancer Center, 2025 - Present
Extramural Institutional Committee Activities
Faculty Representative, Chair Search Committee - Biostatistics, The University of Texas MD Anderson Cancer Center, 2023 - Present
Faculty Representative, Research Integrity, The University of Texas MD Anderson Cancer Center, 2023 - Present
Faculty Representative, Chair Search Committee - Systems Biology, The University of Texas MD Anderson Cancer Center, 2021 - Present
Faculty Representative, Chair Search Committee - Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 2021 - Present
Faculty Representative, Executive Search Committee - DQS IT, The University of Texas MD Anderson Cancer Center, 2018 - Present
Senator, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2018 - Present
Executive Committee member, Functional Genomics Core, The University of Texas MD Anderson Cancer Center, 2017 - Present
Honors & Awards
| 2023 | Faculty Scholar Award |
| 2020 | Sabin Family Foundation Award |
| 2016 | CPRIT Recruitment of First-time Tenure-Track Faculty Award |
| 2016 | University of Texas Rising STARs Award |
Professional Memberships
Selected Presentations & Talks
National Presentations
- 2025. Network-guided genetic interaction screens. Invited. Cambridge, MA, US.
- 2025. Network-guided genetic interaction screens. Invited. CSHL Networks & Systems Biology. Cold Spring Harbor, NY, US.
- 2022. Predicting genetic interactions in mammalian cells. Conference. Predicting genetic interactions in mammalian cells. Cold Spring Harbor, NY, US.
- 2021. CRISPR screening for functional genomics and cancer targeting. Conference. CRISPR screening for functional genomics and cancer targeting. St Louis, MO, US.
- 2020. Biases and Blind Spots in CRISPR fitness screens. Conference. Biases and Blind Spots in CRISPR fitness screens. (virtual), US.
- 2020. Understanding the hierarchical organization of the cell through cancer mutational rewiring. Conference. Understanding the hierarchical organization of the cell through cancer mutational rewiring. Nashua, NJ, US.
- 2020. CRISPR-mediated target finding - and its weaknesses. Conference. CRISPR-mediated target finding - and its weaknesses. NY, NY, US.
- 2019. Discovering moonlighting proteins from human functional interaction networks. Conference. Discovering moonlighting proteins from human functional interaction networks. Cold Spring Harbor, NY, US.
- 2019. Hierarchical organization of the human cell. Conference. Hierarchical organization of the human cell. Washington, DC, US.
- 2018. Hierarchical organization of a human cell. Conference. Hierarchical organization of a human cell. Seoul.
- 2015. Finding essential human genes with an ultracomplex CRISPR-Cas9 library. Conference. Finding essential human genes with an ultracomplex CRISPR-Cas9 library. Cold Spring Harbor, NY, US.
- 2014. Functional genomics and cancer subtyping with a human cancer coessentiality network. Conference. Functional genomics and cancer subtyping with a human cancer coessentiality network. Boston, MA, US.
- 2013. Protein complexes are central to human gene essentiality and genetic interaction studies. Conference. Protein complexes are central to human gene essentiality and genetic interaction studies. Cold Spring Harbor, NY, US.
International Presentations
- 2025. Network-guided genetic interaction screens. Invited. CRISPRMed. Copenhagen, DK.
- 2024. Network-guided genetic interaction screens. Invited. Frankfurt, DE.
- 2024. Multiplex Genetic Perturbation Screens for Understanding Cellular Function. Invited. 1st Annual Bellairs Meeting on Genome Engineering and Repair. Holetown, BB.
- 2024. Multiplex Genetic Perturbation Screens for Understanding Cellular Function. Invited. Frankfurt, DE.
- 2024. Multiplex Genetic Perturbation Screens for Understanding Cellular Function. Invited. Zurich, CH.
- 2023. Multiplex CRISPR for target finding and genetic modeling of drug response. Invited. MDACC/CRO Aviano Joint Meeting. Pordenone, IT.
- 2023. CRISPR multiplexing for synthetic lethality and genetic modeling of polypharmacology. Conference. CRISPR multiplexing for synthetic lethality and genetic modeling of polypharmacology. Oxford, GB.
- 2022. The IN4MER library for genetic interactions in mammalian cells. Conference. The IN4MER library for genetic interactions in mammalian cells. Hinxton, GB.
- 2019. Capabilities and caveats of CRISPR-mediated drug modifier screens. Conference. Roche. Basel, CH.
- 2019. Biases and Blind Spots in CRISPR fitness screens. Conference. Biases and Blind Spots in CRISPR fitness screens. Hinxton, GB.
- 2019. Hierarchical organization of the human cell. Conference. Hierarchical organization of the human cell. Nassau, BS.
- 2018. Hierarchical organization of a human cell. Conference. Hierarchical organization of a human cell. Seefeld, AT.
- 2016. Optimizing CRISPR knockout screens for cancer targeting and functional genomics. Conference. Optimizing CRISPR knockout screens for cancer targeting and functional genomics. Heidelberg, DE.
- 2015. Finding essential human genes with an ultracomplex CRISPR-Cas9 library. Conference. Finding essential human genes with an ultracomplex CRISPR-Cas9 library. Toronto, CA.
Formal Peers
- 2023. CRISPR multiplexing for synthetic lethality and genetic modeling of polypharmacology. Invited. Basel, CH.
- 2023. CRISPR multiplexing for synthetic lethality and genetic modeling of polypharmacology. Invited. Lausanne, CH.
- 2022. CRISPR technologies for functional genomics and cancer target finding. Invited. Portland, OR, US.
- 2022. CRISPR technologies for functional genomics and cancer target finding. Invited. Pittsburgh, PA, US.
- 2021. The many challenges of genetic interactions in mammalian cells. Invited. Heidelberg, DE.
- 2021. The many challenges of genetic interactions in mammalian cells. Invited. Austin, TN, US.
- 2020. Biases and Blind Spots in CRISPR fitness screens. Invited. Hinxton, GB.
- 2019. Precision functional genomics in human cells: vignettes from DepMap data. Invited. Cambridge, MA, US.
- 2019. Biases and Blind Spots in CRISPR fitness screens. Invited. Austin, TX, US.
- 2018. Hierarchical organization of a human cell. Invited. South San Francisco, CA, US.
- 2018. Hierarchical organization of a human cell. Invited.
- 2018. Hierarchical organization of a human cell. Invited. Dublin, IE.
- 2018. Hierarchical organization of a human cell. Invited. Los Angeles, CA, US.
- 2018. Where are all the essential genes? Lessons from 400 CRISPR screens in cancer cell lines. Invited. Montreal, Quebec, CA.
- 2016. Optimizing CRISPR knockout screens for cancer targeting and functional genomics. Invited. Heidelberg, DE.
- 2016. Optimizing CRISPR knockout screens for cancer targeting and functional genomics. Invited. Amsterdam, NL.
- 2012. The noisy human transcriptome: implications for the design and analysis of RNA-seq experiments. Invited. Toronto, Ontario, CA.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Efficient Measurement and Characterization of Genetic Interactions in Cancer Cells |
| Funding Source: | NCI |
| Role: | PI |
| ID: | R01CA303638 |
| Date: | 2023 - 2028 |
| Title: | Deciphering the hierarchical modularity of the cell through multiplex CRISPR perturbation strategies |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | FP18635 |
| Date: | 2023 - 2028 |
| Title: | Accurate Prediction and Efficient Measurement of Genetic Interactions in Cancer Cells |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA286573-01 |
| Date: | 2023 - 2028 |
| Title: | Deciphering the hierarchical modularity of the cell through multiplex CRISPR perturbation strategies |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| ID: | R35 GM130119 |
| Date: | 2023 - 2028 |
| Title: | Deciphering the hierarchical modularity of the mammalian cell through network integration and complex genetic perturbation strategies |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| ID: | 2R35GM130119-06 |
| Date: | 2023 - 2028 |
| Title: | Medical Students Summer in Oncology at Anderson Research (Med Students SOAR) program |
| Funding Source: | NIH/NCI |
| Role: | Preceptor |
| ID: | FP00012837_Res1 |
| Date: | 2023 - 2028 |
| Title: | Molecular and Immunologic Strategies in GIST SPORE |
| Funding Source: | Sarcoma Alliance for Research through Collaboration |
| Role: | PI |
| ID: | 1P50CA272389-01 |
| Date: | 2023 - 2028 |
| Title: | Identifying and targeting collateral lethal vulnerabilities in cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1 U01 CA275886-01 |
| Date: | 2023 - 2027 |
| Title: | Targeting ferroptosis in cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA269646-01A1 |
| Date: | 2022 - 2027 |
| Title: | PATIENT-DERIVED XENOGRAFT AND ADVANCED IN VIVO MODELS (PDX-AIM) CORE FACILITY OF TEXAS |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP220646 |
| Date: | 2022 - 2029 |
| Title: | Biology and Function of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1R35CA263815-01A1 |
| Date: | 2022 - 2027 |
| Title: | BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE U54 PROGRAM (BAATAAR-UP): Project 2 |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1U54CA224081-01 |
| Date: | 2022 - 2025 |
| Title: | BC211194: Targeting PARG for inhibition in PARPi-resistant breast cancer tumors |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| ID: | W81XWH-21 |
| Date: | 2022 - 2027 |
| Title: | Pancreatic Cancer Prevention and Interception Targeted Discovery Center (PanCa-PIT) |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1 U54 CA272685-01 |
| Date: | 2022 - 2027 |
| Title: | Molecular and Immunologic Strategies in GIST SPORE |
| Funding Source: | Sarcoma Alliance for Research through Collaboration |
| Role: | Principal Investigator-MDACC |
| ID: | FP00013630 |
| Date: | 2022 - 2027 |
| Title: | MIPS Center: Targeted Interception Program to Develop Molecular and Immunologic Prevention Strategies |
| Funding Source: | NIH/NCI |
| Role: | Program Leader |
| ID: | 1 U54 CA272535-01 |
| Date: | 2022 - 2027 |
| Title: | Targeting ferroptosis in cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1 R01 CA269646-01 |
| Date: | 2022 - 2025 |
| Title: | Study AMPK in ferroptosis regulation: mechanisms and preclinical translation |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Other Significant Contributor |
| ID: | RP220258 |
| Date: | 2021 - 2024 |
| Title: | Identification of collateral lethal targets in prostate cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | CO-I |
| ID: | W81XWH-21-1-0766 |
| Date: | 2021 - 2023 |
| Title: | Multiplex CRISPR genetic modeling of polypharmacology for precision medicine |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP210173 |
| Date: | 2021 - 2023 |
| Title: | Identification of collateral lethal and synthetic lethal targets in pancreatic and colorectal cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | CO-I |
| ID: | RP210073 |
| Date: | 2021 - 2028 |
| Title: | Biology and Function of Exosomes in Cancer |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R35CA263815 |
| Date: | 2021 - 2026 |
| Title: | Characterization of Functional Regulatory Elements During T-Cell Differentiation |
| Funding Source: | NHGRI |
| Role: | Principal Investigator-MDACC |
| ID: | UM1HG012063 |
| Date: | 2021 - 2022 |
| Title: | Identification of synthetic lethal and collateral lethal targets in prostate cancer |
| Funding Source: | Koch Foundation |
| Role: | Principal Investigator-MDACC |
| ID: | 188000-80-123287-21 |
| Date: | 2021 - 2026 |
| Title: | Pharmacological Modulation of Poly(ADP-Ribose) Metabolism |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 2R01CA200231-07 |
| Date: | 2021 - 2026 |
| Title: | Characterizing and exploiting the plasticity of lipid metabolism in myeloid leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | U01 CA260435 |
| Date: | 2021 - 2023 |
| Title: | Combinatorial polygenic loss of function libraries for high-dimensional synthetic lethality and genetic interactions |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21 CA260022 |
| Date: | 2020 - 2025 |
| Title: | The role of unsaturated fatty acid (UFA) metabolism in regulating intracellular vesicle trafficking of neural/glioma stem cells during neural development and gliomagenesis |
| Funding Source: | NIH/NINDS |
| Role: | Collaborator |
| ID: | R01 NS115769 |
| Date: | 2020 - 2021 |
| Title: | Differential lipid metabolism defines an actionable subtype of myeloid leukemia |
| Funding Source: | When Everyone Survives |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation |
| Funding Source: | NIH/NCI |
| Role: | Other significant contributor |
| ID: | 5 R01 CA 247992 - 02 |
| Date: | 2020 - 2025 |
| Title: | Advanced mammalian models for identification of novel drug combinations effective for non small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R01CA255117 |
| Date: | 2020 - 2025 |
| Title: | Collateral Lethality Targeting of the PTEN Locus |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1R01 CA255514-01 |
| Date: | 2020 - 2025 |
| Title: | Study AMPK in ferroptosis regulation: mechanisms and preclinical translation |
| Funding Source: | NIH/NCI |
| Role: | Other significant contributor |
| ID: | 1R01 CA255027-01 |
| Date: | 2020 - 2025 |
| Title: | Expanding the known coding genome: identifying biological function for novel tORFs |
| Funding Source: | NIH/NIGMS |
| Role: | CO-I |
| ID: | R01 GM139980-01 |
| Date: | 2020 - 2025 |
| Title: | Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translation |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 5 R01 CA 244144 - 02 |
| Date: | 2020 - 2025 |
| Title: | Overcoming Resistance to Targeted Therapies in HER2+ Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R01 CA251610 |
| Date: | 2020 - 2025 |
| Title: | Enhancer RNA Innate Immunity |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| Date: | 2020 - 2025 |
| Title: | LoxL2 and H3K4 methylation as effectors of anti-PD1 response in melanoma |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | 1R01CA231146-01A1 |
| Date: | 2020 - 2025 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5 R01 CA082577-04 |
| Date: | 2019 - 2024 |
| Title: | Characterizing and Targeting Oncogenic Enhancer-derived RNAs in Breast Cancer |
| Funding Source: | University of Texas Health Science Center (Subaward via NIH) |
| Role: | CO-I |
| Date: | 2019 - 2024 |
| Title: | Role of p53 Missense Mutations on Tumorigenesis in Vivo |
| Funding Source: | NIH/NCI |
| Role: | CO-I |
| ID: | R01 CA082577 |
| Date: | 2019 - 2022 |
| Title: | Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | K22 CA241113 |
| Date: | 2019 - 2024 |
| Title: | Integrative approaches for decoding the function and regulation of unconventional RNA translation |
| Funding Source: | NIH/NIGMS |
| Role: | Collaborator |
| ID: | R01 GM130838-01A1 |
| Date: | 2019 - 2020 |
| Title: | Identifying and Targeting Vulnerabilities in Primary Triple Negative Breast Cancer |
| Funding Source: | Breast Cancer Alliance |
| Role: | CO-I |
| ID: | FP6100 |
| Date: | 2018 - 2023 |
| Title: | Exploiting Patterns of Gene Essentiality in Human Cells to Predict Gene Function, Synthetic Lethality, and Cancer Targets |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| ID: | 5R35GM130119-05 |
| Date: | 2018 - 2019 |
| Title: | Synthetic essential approach to identify novel therapeutic targets for prostate cancer |
| Funding Source: | Prostate Cancer Foundation |
| Role: | CO-I |
| ID: | N/A |
| Date: | 2016 - 2021 |
| Title: | Recruitment of First-time Tenure-Track Faculty |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR160032 |
Selected Publications
Peer-Reviewed Articles
- Chou, J, Esmaeili Anvar, N, Elghaish, R, Chen, J, Hart, T. Z-scores outperform similar methods for analyzing CRISPR paralog synthetic lethality screens. Genome biology 26(1), 2025. e-Pub 2025. PMID: 40605002.
- Makino Y, Rajapakshe KI, Chellakkan Selvanesan B, Okumura T, Date K, Dutta P, Abou-Elkacem L, Sagara A, Min J, Sans M, Yee N, Siemann MJ, Enriquez J, Smith P, Bhattacharya P, Kim M, Dede M, Hart T, Maitra A, Thege FI. Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas. Gut 74(1):75-88, 2024. e-Pub 2024. PMID: 39277181.
- Feng X, Yang C, Huang Y, Su D, Wang C, Wilson LL, Yin L, Tang M, Li S, Chen Z, Zhu D, Wang S, Zhang S, Zhang J, Zhang H, Nie L, Huang M, Park JI, Hart T, Jiang D, Jiang K, Chen J. In vivo CRISPR screens identify Mga as an immunotherapy target in triple-negative breast cancer. Proc Natl Acad Sci U S A 121(39):e2406325121, 2024. e-Pub 2024. PMID: 39298484.
- Esmaeili Anvar N, Lin C, Ma X, Wilson LL, Steger R, Sangree AK, Colic M, Wang SH, Doench JG, Hart T. Efficient gene knockout and genetic interaction screening using the in4mer CRISPR/Cas12a multiplex knockout platform. Nat Commun 15(1):3577, 2024. e-Pub 2024. PMID: 38678031.
- Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland Iii JA, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight, 2023. e-Pub 2023. PMID: 38060314.
- Huang M, Yao F, Nie L, Wang C, Su D, Zhang H, Li S, Tang M, Feng X, Yu B, Chen Z, Wang S, Yin L, Mou L, Hart T, Chen J. FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways. Mol Cell 83(15):2810-2828.e6, 2023. e-Pub 2023. PMID: 37541219.
- Patel LR, Stratton SA, McLaughlin M, Krause P, Allton K, Rivas AL, Barbosa D, Hart T, Barton MC. Genome-wide CRISPR-Cas9 screen analyzed by SLIDER identifies network of repressor complexes that regulate TRIM24. iScience 26(7):107126, 2023. e-Pub 2023. PMID: 37426340.
- Park JM, Zhang H, Nie L, Wang C, Huang M, Feng X, Tang M, Chen Z, Xiong Y, Lee N, Li S, Yin L, Hart T, Chen J. Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway. Int J Mol Sci 24(7), 2023. e-Pub 2023. PMID: 37047518.
- Liu X, Nie L, Zhang Y, Yan Y, Wang C, Colic M, Olszewski K, Horbath A, Chen X, Lei G, Mao C, Wu S, Zhuang L, Poyurovsky MV, James You M, Hart T, Billadeau DD, Chen J, Gan B. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis. Nat Cell Biol 25(3):404-414, 2023. e-Pub 2023. PMID: 36747082.
- Dede M, Hart T. Recovering false negatives in CRISPR fitness screens with JLOE. Nucleic Acids Res 51(4):1637-1651, 2023. e-Pub 2023. PMID: 36727483.
- Novak LC, Chou J, Colic M, Bristow CA, Hart T. PICKLES v3: the updated database of pooled in vitro CRISPR knockout library essentiality screens. Nucleic Acids Res 51(D1):D1117-D1121, 2023. e-Pub 2023. PMID: 36350677.
- Gheorghe V, Hart T. Optimal construction of a functional interaction network from pooled library CRISPR fitness screens. BMC Bioinformatics 23(1):510, 2022. e-Pub 2022. PMID: 36443674.
- Kim E, Novak LC, Lin C, Colic M, Bertolet LL, Gheorghe V, Bristow CA, Hart T. Dynamic rewiring of biological activity across genotype and lineage revealed by context-dependent functional interactions. Genome Biol 23(1):140, 2022. e-Pub 2022. PMID: 35768873.
- Wang C, Feng X, Su D, Chen Z, Wang S, Tang M, Huang M, Nie L, Zhang H, Li S, Yin L, Johnson RL, Hart T, Chen J. Integrated screens uncover a cell surface tumor suppressor gene KIRREL involved in Hippo pathway. Proc Natl Acad Sci U S A 119(25):e2121779119, 2022. e-Pub 2022. PMID: 35704761.
- Feng X, Tang M, Dede M, Su D, Pei G, Jiang D, Wang C, Chen Z, Li M, Nie L, Xiong Y, Li S, Park JM, Zhang H, Huang M, Szymonowicz K, Zhao Z, Hart T, Chen J. Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors. Sci Adv 8(19):eabm6638, 2022. e-Pub 2022. PMID: 35559673.
- Kim CY, Baek S, Cha J, Yang S, Kim E, Marcotte EM, Hart T, Lee I. HumanNet v3: an improved database of human gene networks for disease research. Nucleic Acids Res 50(D1):D632-D639, 2022. e-Pub 2022. PMID: 34747468.
- Lenoir WF, Morgado M, DeWeirdt PC, McLaughlin M, Griffith AL, Sangree AK, Feeley MN, Esmaeili Anvar N, Kim E, Bertolet LL, Colic M, Dede M, Doench JG, Hart T. Discovery of putative tumor suppressors from CRISPR screens reveals rewired lipid metabolism in acute myeloid leukemia cells. Nat Commun 12(1):6506, 2021. e-Pub 2021. PMID: 34764293.
- Yoshihama Y, LaBella KA, Kim E, Bertolet L, Colic M, Li J, Shang X, Wu CJ, Spring DJ, Wang YA, Hart T, DePinho RA. AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase. Proc Natl Acad Sci U S A 118(36), 2021. e-Pub 2021. PMID: 34475205.
- Wang C, Tang M, Chen Z, Nie L, Li S, Xiong Y, Szymonowicz KA, Park JM, Zhang H, Feng X, Huang M, Su D, Hart T, Chen J. Genetic vulnerabilities upon inhibition of DNA damage response. Nucleic Acids Res 49(14):8214-8231, 2021. e-Pub 2021. PMID: 34320214.
- Kim E, Hart T. Improved analysis of CRISPR fitness screens and reduced off-target effects with the BAGEL2 gene essentiality classifier. Genome Med 13(1):2, 2021. e-Pub 2021. PMID: 33407829.
- Wang R, Lenoir WF, Wang C, Su D, McLaughlin M, Hu Q, Shen X, Tian Y, Klages-Mundt N, Lynn E, Wood RD, Chen J, Hart T, Li L. DNA polymerase ι compensates for Fanconi anemia pathway deficiency by countering DNA replication stress. Proc Natl Acad Sci U S A 117(52):33436-33445, 2020. e-Pub 2020. PMID: 33376220.
- Wang C, Chen Z, Su D, Tang M, Nie L, Zhang H, Feng X, Wang R, Shen X, Srivastava M, McLaughlin ME, Hart T, Li L, Chen J. C17orf53 is identified as a novel gene involved in inter-strand crosslink repair. DNA Repair (Amst) 95:102946, 2020. e-Pub 2020. PMID: 32853826.
- Dede M, McLaughlin M, Kim E, Hart T. Multiplex enCas12a screens detect functional buffering among paralogs otherwise masked in monogenic Cas9 knockout screens. Genome Biol 21(1):262, 2020. e-Pub 2020. PMID: 33059726.
- Lawson KA, Sousa CM, Zhang X, Kim E, Akthar R, Caumanns JJ, Yao Y, Mikolajewicz N, Ross C, Brown KR, Zid AA, Fan ZP, Hui S, Krall JA, Simons DM, Slater CJ, De Jesus V, Tang L, Singh R, Goldford JE, Martin S, Huang Q, Francis EA, Habsid A, Climie R, Tieu D, Wei J, Li R, Tong AHY, Aregger M, Chan KS, Han H, Wang X, Mero P, Brumell JH, Finelli A, Ailles L, Bader G, Smolen GA, Kingsbury GA, Hart T, Kung C, Moffat J. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature 586(7827):120-126, 2020. e-Pub 2020. PMID: 32968282.
- Aubert L, Nandagopal N, Steinhart Z, Lavoie G, Nourreddine S, Berman J, Saba-El-Leil MK, Papadopoli D, Lin S, Hart T, Macleod G, Topisirovic I, Gaboury L, Fahrni CJ, Schramek D, Meloche S, Angers S, Roux PP. Copper bioavailability is a KRAS-specific vulnerability in colorectal cancer. Nat Commun 11(1):3701, 2020. e-Pub 2020. PMID: 32709883.
- Huang M, Feng X, Su D, Wang G, Wang C, Tang M, Paulucci-Holthauzen A, Hart T, Chen J. Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition. Oncogene 39(21):4312-4322, 2020. e-Pub 2020. PMID: 32300176.
- Wertz MH, Mitchem MR, Pineda SS, Hachigian LJ, Lee H, Lau V, Powers A, Kulicke R, Madan GK, Colic M, Therrien M, Vernon A, Beja-Glasser VF, Hegde M, Gao F, Kellis M, Hart T, Doench JG, Heiman M. Genome-wide In Vivo CNS Screening Identifies Genes that Modify CNS Neuronal Survival and mHTT Toxicity. Neuron 106(1):76-89.e8, 2020. e-Pub 2020. PMID: 32004439.
- Su D, Feng X, Colic M, Wang Y, Zhang C, Wang C, Tang M, Hart T, Chen J. CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions. DNA Repair (Amst) 87:102803, 2020. e-Pub 2020. PMID: 31991288.
- Mis M, O'Brien S, Steinhart Z, Lin S, Hart T, Moffat J, Angers S. IPO11 mediates βcatenin nuclear import in a subset of colorectal cancers. J Cell Biol 219(2), 2020. e-Pub 2020. PMID: 31881079.
- Hustedt N, Álvarez-Quilón A, McEwan A, Yuan JY, Cho T, Koob L, Hart T, Durocher D. A consensus set of genetic vulnerabilities to ATR inhibition. Open Biol 9(9):190156, 2019. e-Pub 2019. PMID: 31506018.
- Colic M, Wang G, Zimmermann M, Mascall K, McLaughlin M, Bertolet L, Lenoir WF, Moffat J, Angers S, Durocher D, Hart T. Identifying chemogenetic interactions from CRISPR screens with drugZ. Genome Med 11(1):52, 2019. e-Pub 2019. PMID: 31439014.
- Liu J, Srinivasan S, Li CY, Ho IL, Rose J, Shaheen M, Wang G, Yao W, Deem A, Bristow C, Hart T, Draetta G. Pooled library screening with multiplexed Cpf1 library. Nat Commun 10(1):3144, 2019. e-Pub 2019. PMID: 31316073.
- MacLeod G, Bozek DA, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z, Kushida MM, Yu H, Coutinho FJ, Cavalli FMG, Restall I, Hao X, Hart T, Luchman HA, Weiss S, Dirks PB, Angers S. Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Rep 27(3):971-986.e9, 2019. e-Pub 2019. PMID: 30995489.
- Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition. Oncogene 38(14):2451-2463, 2019. e-Pub 2019. PMID: 30532030.
- Kim E, Dede M, Lenoir WF, Wang G, Srinivasan S, Colic M, Hart T. A network of human functional gene interactions from knockout fitness screens in cancer cells. Life Sci Alliance 2(2), 2019. e-Pub 2019. PMID: 30979825.
- Nixon AML, Duque A, Yelle N, McLaughlin M, Davoudi S, Pedley NM, Haynes J, Brown KR, Pan J, Hart T, Gilbert PM, Singh SK, O'Brien CA, Sidhu SS, Moffat J. A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations. Sci Rep 9(1):842, 2019. e-Pub 2019. PMID: 30696911.
- Hwang S, Kim CY, Yang S, Kim E, Hart T, Marcotte EM, Lee I. HumanNet v2: human gene networks for disease research. Nucleic Acids Res 47(D1):D573-D580, 2019. e-Pub 2019. PMID: 30418591.
- Podshivalova K, Wang EA, Hart T, Salomon DR. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line. Leuk Res 74:1-9, 2018. e-Pub 2018. PMID: 30269036.
- Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. The Shieldin complex mediates 53BP1-dependent DNA repair. Nature 560(7716):117-121, 2018. e-Pub 2018. PMID: 30022168.
- Zimmermann M, Murina O, Reijns MAM, Agathanggelou A, Challis R, Ž T, Muir M, Fluteau A, Aregger M, McEwan A, Yuan W, Clarke M, Lambros MB, Paneesha S, Moss P, Chandrashekhar M, Angers S, Moffat J, Brunton VG, Hart T, de Bono J, Stankovic T, Jackson AP, Durocher D. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions. Nature 559(7713):285-289, 2018. e-Pub 2018. PMID: 29973717.
- Lenoir WF, Lim TL, Hart T. PICKLES: the database of pooled in-vitro CRISPR knockout library essentiality screens. Nucleic Acids Res 46(D1):D776-D780, 2018. e-Pub 2018. PMID: 29077937.
- Hart T, Tong AHY, Chan K, Van Leeuwen J, Seetharaman A, Aregger M, Chandrashekhar M, Hustedt N, Seth S, Noonan A, Habsid A, Sizova O, Nedyalkova L, Climie R, Tworzyanski L, Lawson K, Sartori MA, Alibeh S, Tieu D, Masud S, Mero P, Weiss A, Brown KR, Usaj M, Billmann M, Rahman M, Constanzo M, Myers CL, Andrews BJ, Boone C, Durocher D, Moffat J. Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens. G3 (Bethesda) 7(8):2719-2727, 2017. e-Pub 2017. PMID: 28655737.
- Steinhart Z, Pavlovic Z, Chandrashekhar M, Hart T, Wang X, Zhang X, Robitaille M, Brown KR, Jaksani S, Overmeer R, Boj SF, Adams J, Pan J, Clevers H, Sidhu S, Moffat J, Angers S. Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Nat Med 23(1):60-68, 2017. e-Pub 2017. PMID: 27869803.
- Hart T, Moffat J. BAGEL: a computational framework for identifying essential genes from pooled library screens. BMC Bioinformatics 17:164, 2016. e-Pub 2016. PMID: 27083490.
- Toledo CM, Ding Y, Hoellerbauer P, Davis RJ, Basom R, Girard EJ, Lee E, Corrin P, Hart T, Bolouri H, Davison J, Zhang Q, Hardcastle J, Aronow BJ, Plaisier CL, Baliga NS, Moffat J, Lin Q, Li XN, Nam DH, Lee J, Pollard SM, Zhu J, Delrow JJ, Clurman BE, Olson JM, Paddison PJ. Genome-wide CRISPR-Cas9 Screens Reveal Loss of Redundancy between PKMYT1 and WEE1 in Glioblastoma Stem-like Cells. Cell Rep 13(11):2425-39, 2015. e-Pub 2015. PMID: 26673326.
- Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, MacLeod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, Mero P, Dirks P, Sidhu S, Roth FP, Rissland OS, Durocher D, Angers S, Moffat J. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell 163(6):1515-26, 2015. e-Pub 2015. PMID: 26627737.
- Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, Penn LZ. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget 6(29):26909-21, 2015. e-Pub 2015. PMID: 26353928.
- Vu V, Verster AJ, Schertzberg M, Chuluunbaatar T, Spensley M, Pajkic D, Hart GT, Moffat J, Fraser AG. Natural Variation in Gene Expression Modulates the Severity of Mutant Phenotypes. Cell 162(2):391-402, 2015. e-Pub 2015. PMID: 26186192.
- Komori HK, Hart T, LaMere SA, Chew PV, Salomon DR. Defining CD4 T cell memory by the epigenetic landscape of CpG DNA methylation. J Immunol 194(4):1565-79, 2015. e-Pub 2015. PMID: 25576597.
- Hart T, Brown KR, Sircoulomb F, Rottapel R, Moffat J. Measuring error rates in genomic perturbation screens: gold standards for human functional genomics. Mol Syst Biol 10:733, 2014. e-Pub 2014. PMID: 24987113.
- Hart T, Komori HK, LaMere S, Podshivalova K, Salomon DR. Finding the active genes in deep RNA-seq gene expression studies. BMC Genomics 14:778, 2013. e-Pub 2013. PMID: 24215113.
- Havugimana PC, Hart GT, Nepusz T, Yang H, Turinsky AL, Li Z, Wang PI, Boutz DR, Fong V, Phanse S, Babu M, Craig SA, Hu P, Wan C, Vlasblom J, Dar VU, Bezginov A, Clark GW, Wu GC, Wodak SJ, Tillier ER, Paccanaro A, Marcotte EM, Emili A. A census of human soluble protein complexes. Cell 150(5):1068-81, 2012. e-Pub 2012. PMID: 22939629.
- Komori HK, LaMere SA, Torkamani A, Hart GT, Kotsopoulos S, Warner J, Samuels ML, Olson J, Head SR, Ordoukhanian P, Lee PL, Link DR, Salomon DR. Application of microdroplet PCR for large-scale targeted bisulfite sequencing. Genome Res 21(10):1738-45, 2011. e-Pub 2011. PMID: 21757609.
- Grigoryev YA, Kurian SM, Hart T, Nakorchevsky AA, Chen C, Campbell D, Head SR, Yates JR, Salomon DR. MicroRNA regulation of molecular networks mapped by global microRNA, mRNA, and protein expression in activated T lymphocytes. J Immunol 187(5):2233-43, 2011. e-Pub 2011. PMID: 21788445.
- Head SR, Komori HK, Hart GT, Shimashita J, Schaffer L, Salomon DR, Ordoukhanian PT. Method for improved Illumina sequencing library preparation using NuGEN Ovation RNA-Seq System. Biotechniques 50(3):177-80, 2011. e-Pub 2011. PMID: 21486238.
- Niu W, Hart GT, Marcotte EM. High-throughput immunofluorescence microscopy using yeast spheroplast cell-based microarrays. Methods Mol Biol 706:83-95, 2011. e-Pub 2011. PMID: 21104056.
- Narayanaswamy R, Moradi EK, Niu W, Hart GT, Davis M, McGary KL, Ellington AD, Marcotte EM. Systematic definition of protein constituents along the major polarization axis reveals an adaptive reuse of the polarization machinery in pheromone-treated budding yeast. J Proteome Res 8(1):6-19, 2009. e-Pub 2009. PMID: 19053807.
- Hart T, Zhao A, Garg A, Bolusani S, Marcotte EM. Human cell chips: adapting DNA microarray spotting technology to cell-based imaging assays. PLoS One 4(10):e7088, 2009. e-Pub 2009. PMID: 19862318.
- Ramani AK, Li Z, Hart GT, Carlson MW, Boutz DR, Marcotte EM. A map of human protein interactions derived from co-expression of human mRNAs and their orthologs. Mol Syst Biol 4:180, 2008. e-Pub 2008. PMID: 18414481.
- Hart GT, Lee I, Marcotte ER. A high-accuracy consensus map of yeast protein complexes reveals modular nature of gene essentiality. BMC Bioinformatics 8:236, 2007. e-Pub 2007. PMID: 17605818.
- Hart GT, Ramani AK, Marcotte EM. How complete are current yeast and human protein-interaction networks?. Genome Biol 7(11):120, 2006. e-Pub 2006. PMID: 17147767.
- Narayanaswamy R, Niu W, Scouras AD, Hart GT, Davies J, Ellington AD, Iyer VR, Marcotte EM. Systematic profiling of cellular phenotypes with spotted cell microarrays reveals mating-pheromone response genes. Genome Biol 7(1):R6, 2006. e-Pub 2006. PMID: 16507139.
Invited Articles
- Colic M, Hart T. Common computational tools for analyzing CRISPR screens. Emerg Top Life Sci 5(6):779-788, 2021. e-Pub 2021. PMID: 34881774.
- Colic M, Hart T. Chemogenetic interactions in human cancer cells. Comput Struct Biotechnol J 17:1318-1325, 2019. e-Pub 2019. PMID: 31921397.
Editorials
- Kim E, Hart T. All for One, and One for All. Cell Syst 5(4):314-316, 2017. PMID: 29073370.
- Aregger M, Hart T, Moffat J. Extensive mapping of an innate immune network with CRISPR. Mol Syst Biol 11(7):821, 2015. PMID: 26208794.
- Hart T, Moffat J. Scaling up the systematic hunt for mammalian genetic interactions. Nat Methods 10(5):397-9, 2013. PMID: 23629415.
Abstracts
- Hart GT. Echoes of human genetic interactions? Essential protein complexes show lower genetic variation, 2012. e-Pub 2012.
- Hart GT, Komori K. DNA methylation analysis of targeted promoter regions at single nucleotide resolution. Systems Biology: Networks, 2011. e-Pub 2011.
- Hart GT, Komori K. Ten million reads for accurate, efficient measurement of differential expression in mammals by RNA-seq. Functional Genomics and Systems Biology, 2011. e-Pub 2011.
- Hart GT, I Lee I. A high-accuracy consensus map of yeast protein complexes reveals modular nature of gene essentiality. Gordon Research Conference on Bioinformatics, 2007. e-Pub 2007.
- Hart GT, I Lee I. Separating the wheat from the chaff: a highly accurate subset of yeast protein complexes, 2006. e-Pub 2006.
- Hart GT, AK Ramani AK. On the road to mapping the human and yeast interactomes: are we there yet?, 2005. e-Pub 2005.
Patient Reviews
CV information above last modified July 22, 2026